The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.
Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.
We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF α-synuclein species as surrogate biomarkers for Parkinson’s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]
A critical component of PPMI is the standardized, longitudinal collection of biospecimens. Each month the Biospecimen Review Committee examines requests for biospecimens collected through the PPMI study. We are excited to announce approval for Dr. Martin Rabey, the Chief Medical Officer of BioShai Ltd, for a project entitled: Validation of a blood based gene expression […]
PPMI’s updated study protocol (version 11.0) allows for subjects enrolled in the Parkinson’s Disease (PD) and Healthy Control cohorts to continue participation in PPMI beyond month 60. Subjects in these two cohorts consenting to amendment 10 will be followed through month 96 (V15). Subjects in the PD cohort will continue with annual in person visits […]